US4160452A
(en)
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
US5169645A
(en)
|
1989-10-31 |
1992-12-08 |
Duquesne University Of The Holy Ghost |
Directly compressible granules having improved flow properties
|
US6316003B1
(en)
|
1989-12-21 |
2001-11-13 |
Whitehead Institute For Biomedical Research |
Tat-derived transport polypeptides
|
US5292638A
(en)
|
1990-12-07 |
1994-03-08 |
The Regents Of The University Of California |
Method of determining functional estrogen receptors for prognosis of cancer
|
DK0632720T3
(da)
|
1992-03-25 |
1999-07-26 |
Depomed Inc |
Hydroxyethylcellulosebaserede depotpræparat-doseringsformer
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
DK0693054T3
(da)
|
1993-04-07 |
1998-10-19 |
Pfizer |
Cycloalkylhydroxyurinstoffer og deres anvendelse som lipoxygenaseinhibitorer
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
US20030036654A1
(en)
|
1994-08-18 |
2003-02-20 |
Holt Dennis A. |
Synthetic multimerizing agents
|
US5510357A
(en)
|
1995-02-28 |
1996-04-23 |
Eli Lilly And Company |
Benzothiophene compounds as anti-estrogenic agents
|
WO1996032937A1
(en)
*
|
1995-04-21 |
1996-10-24 |
Eli Lilly And Company |
Benzothiophenes with novel basic side chains
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1997040065A2
(en)
|
1996-04-24 |
1997-10-30 |
Peptide Therapeutics Limited |
Substrates and inhibitors of proteolytic enzymes
|
CA2204082A1
(en)
|
1996-05-03 |
1997-11-03 |
Michael William John Urquhart |
Pharmaceutical compounds
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
HRP970566A2
(en)
|
1996-10-30 |
1998-08-31 |
Jones Deborah Defeo |
Conjugates useful in the treatment of prostate canser
|
ZA982818B
(en)
*
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Prevention of breast cancer using selective estrogen receptor modulators.
|
ZA982877B
(en)
*
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Treatment of central nervous system disorders with selective estrogen receptor modulators.
|
ATE460423T1
(de)
|
1997-05-14 |
2010-03-15 |
Sloan Kettering Inst Cancer |
Verfahren und zubereitungen zur zerstörung bestimmter proteine
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
PT998271E
(pt)
|
1997-06-06 |
2005-10-31 |
Depomed Inc |
Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
|
AU740597B2
(en)
|
1997-07-10 |
2001-11-08 |
Merck & Co., Inc. |
Conjugates useful in the treatment of prostate cancer
|
DE69832715T2
(de)
|
1997-07-12 |
2007-01-11 |
Cancer Research Technology Ltd. |
Cyclin-abhängige-kinase inhibierende purinderivate
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
AU9386198A
(en)
|
1997-09-10 |
1999-03-29 |
President And Fellows Of Harvard College |
Inducible methods for repressing gene function
|
WO1999015521A1
(en)
*
|
1997-09-23 |
1999-04-01 |
Eli Lilly And Company |
Benzothiophenes
|
US6323219B1
(en)
|
1998-04-02 |
2001-11-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods for treating immunomediated inflammatory disorders
|
AU4093799A
(en)
|
1998-05-22 |
1999-12-13 |
Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and therapies based thereon
|
WO2000022110A2
(en)
|
1998-10-09 |
2000-04-20 |
President And Fellows Of Harvard College |
Targeted proteolysis by recruitment to ubiquitin protein ligases
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
US6858709B1
(en)
|
1999-02-26 |
2005-02-22 |
Oklahoma Medical Research Foundation |
Component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase
|
CA2362520A1
(en)
|
1999-02-26 |
2000-08-31 |
Joan W. Conaway |
Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
|
JP2002543129A
(ja)
|
1999-05-05 |
2002-12-17 |
メルク エンド カムパニー インコーポレーテッド |
抗微生物剤としての新規なプロリン類
|
US7087386B2
(en)
|
1999-06-11 |
2006-08-08 |
The Burnham Institute |
Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
JP2003512339A
(ja)
|
1999-10-19 |
2003-04-02 |
メルク エンド カムパニー インコーポレーテッド |
前立腺癌の治療に有用な複合体
|
MXPA02004413A
(es)
|
1999-11-02 |
2002-09-02 |
Depomed Inc |
Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago.
|
AU1434201A
(en)
*
|
1999-11-19 |
2001-05-30 |
Eli Lilly And Company |
Antithrombotic agents
|
DE60123384T2
(de)
|
2000-02-04 |
2007-08-02 |
DepoMed, Inc., Menlo Park |
Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
|
US6740495B1
(en)
|
2000-04-03 |
2004-05-25 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase assay
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
EP1360205A1
(en)
|
2001-02-16 |
2003-11-12 |
E.I. Dupont De Nemours And Company |
Angiogenesis-inhibitory tripeptides, compositions and their methods of use
|
GB0106953D0
(en)
|
2001-03-20 |
2001-05-09 |
Univ Aberdeen |
Neufofibrillary labels
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
MXPA03011096A
(es)
|
2001-05-29 |
2004-12-06 |
Depomed Dev Ltd |
Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
|
HN2002000136A
(es)
|
2001-06-11 |
2003-07-31 |
Basf Ag |
Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
|
JP4342939B2
(ja)
|
2001-08-03 |
2009-10-14 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ピラゾール誘導キナーゼインヒビターおよびその使用
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
EP1434579B1
(en)
|
2001-10-09 |
2011-06-08 |
Amgen Inc. |
Imidazole derivatives as antiinflammatory agents
|
US20030133927A1
(en)
|
2001-10-10 |
2003-07-17 |
Defeo-Jones Deborah |
Conjugates useful in the treatment of prostate cancer
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
CA2464561A1
(en)
|
2001-10-25 |
2003-05-01 |
Depomed, Inc. |
Methods of treatment using a gastric retained losartan dosage
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US7053046B2
(en)
|
2001-12-21 |
2006-05-30 |
Mcgrath Kevin |
Peptide activators of VEGF
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
EP1519918A1
(en)
|
2002-07-02 |
2005-04-06 |
Novartis AG |
Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
|
US20040053324A1
(en)
|
2002-08-30 |
2004-03-18 |
Brian Wong |
Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
|
US20040114258A1
(en)
|
2002-12-17 |
2004-06-17 |
Harris Richard Alexander |
Device and method for combining dynamic mathematical expressions and other multimedia objects within a document
|
KR20050090415A
(ko)
|
2002-12-25 |
2005-09-13 |
이데미쓰 고산 가부시키가이샤 |
아다만테인 유도체 및 그의 제조 방법
|
WO2004093871A1
(en)
|
2003-03-27 |
2004-11-04 |
Lankenau Institute For Medical Research |
Novel methods for the treatment of cancer
|
WO2004100868A2
(en)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
US7915293B2
(en)
|
2003-05-30 |
2011-03-29 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase inhibitors
|
US20070281907A1
(en)
|
2003-12-22 |
2007-12-06 |
Watkins William J |
Kinase Inhibitor Phosphonate Conjugates
|
BRPI0506883A
(pt)
|
2004-01-16 |
2007-05-29 |
Univ Michigan |
miméticos de smac conformacionalmente comprimidos e seus usos
|
AU2005228950B2
(en)
|
2004-03-23 |
2012-02-02 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
AR048927A1
(es)
|
2004-04-07 |
2006-06-14 |
Novartis Ag |
Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa
|
MEP8409A
(en)
|
2004-06-02 |
2011-12-20 |
|
Fused heterocyclic compound
|
CA2570321C
(en)
|
2004-07-02 |
2013-10-08 |
Genentech, Inc. |
Inhibitors of iap
|
WO2006006065A1
(en)
|
2004-07-08 |
2006-01-19 |
Warner-Lambert Company Llc |
Androgen modulators
|
CN103251953A
(zh)
|
2004-07-19 |
2013-08-21 |
约翰·霍普金斯大学 |
供免疫抑制的flt3抑制剂
|
US7294748B2
(en)
|
2004-10-19 |
2007-11-13 |
Wake Forest University Health Sciences |
Sulfenic acid-reactive compounds and their methods of synthesis
|
WO2006062685A2
(en)
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
GB0426661D0
(en)
|
2004-12-06 |
2005-01-05 |
Isis Innovation |
Pyrrolidine compounds
|
EA019420B1
(ru)
|
2004-12-20 |
2014-03-31 |
Дженентех, Инк. |
Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
|
CN103083644B
(zh)
|
2005-02-25 |
2014-05-28 |
泰特拉洛吉克药业公司 |
Iap二聚体抑制剂
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物
|
US20060252698A1
(en)
|
2005-04-20 |
2006-11-09 |
Malcolm Bruce A |
Compounds for inhibiting cathepsin activity
|
GEP20217221B
(en)
|
2005-05-10 |
2021-02-10 |
Incyte Holdings Corp Us |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
FR2885904B1
(fr)
|
2005-05-19 |
2007-07-06 |
Aventis Pharma Sa |
Nouveaux derives du fluorene, compositions les contenant et utilisation
|
US20070155730A1
(en)
|
2005-08-26 |
2007-07-05 |
Methylgene, Inc. |
Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase
|
DE602006017566D1
(de)
|
2005-08-30 |
2010-11-25 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
US7705022B2
(en)
|
2005-10-27 |
2010-04-27 |
Lankenau Institute For Medical Research |
IDO inhibitors and methods of use thereof
|
CN101395148A
(zh)
|
2006-03-03 |
2009-03-25 |
诺瓦提斯公司 |
N-甲酰基羟胺化合物
|
WO2007101347A1
(en)
|
2006-03-07 |
2007-09-13 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
CN102755318B
(zh)
|
2006-03-29 |
2014-09-10 |
加利福尼亚大学董事会 |
二芳基硫代乙内酰脲化合物
|
CA2648518C
(en)
|
2006-04-11 |
2012-06-26 |
Ramot At Tel Aviv University Ltd. |
Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
|
CA2651072A1
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
WO2007129195A2
(en)
|
2006-05-04 |
2007-11-15 |
Pfizer Products Inc. |
4-pyrimidine-5-amino-pyrazole compounds
|
PL2019671T3
(pl)
|
2006-05-05 |
2015-02-27 |
Univ Michigan Regents |
Związki pośrednie do wytwarzania dwuwartościowych mimetyków Smac
|
JP2009544620A
(ja)
|
2006-07-20 |
2009-12-17 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
自己免疫疾患及び炎症のためのプロリン尿素ccr1アンタゴニスト
|
WO2008014236A1
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
EP2089391B1
(en)
|
2006-11-03 |
2013-01-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
US8518891B2
(en)
|
2006-11-29 |
2013-08-27 |
Longqin Hu |
Chemotherapeutic conjugates and methods of use
|
EP2129668A1
(en)
|
2007-03-07 |
2009-12-09 |
Janssen Pharmaceutica N.V. |
Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
|
EA200970838A1
(ru)
|
2007-03-07 |
2010-02-26 |
Янссен Фармацевтика Н.В. |
ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛИРОВАННЫЕ ТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α
|
EP2137168B1
(en)
|
2007-03-16 |
2016-09-14 |
Lankenau Institute for Medical Research |
Novel ido inhibitors and methods of use thereof
|
US20080233850A1
(en)
|
2007-03-20 |
2008-09-25 |
3M Innovative Properties Company |
Abrasive article and method of making and using the same
|
AU2008240153B2
(en)
|
2007-04-12 |
2013-01-31 |
Joyant Pharmaceuticals, Inc. |
SMAC mimetic dimers and trimers useful as anti-cancer agents
|
NZ580468A
(en)
|
2007-04-13 |
2012-02-24 |
Univ Michigan |
Diazo bicyclic smac mimetics and the uses thereof
|
JP5368428B2
(ja)
|
2007-04-30 |
2013-12-18 |
ジェネンテック, インコーポレイテッド |
Iapのインヒビター
|
US20100203012A1
(en)
|
2007-05-30 |
2010-08-12 |
Aegera Therapeutics, Inc. |
Iap bir domain binding compounds
|
KR20100038108A
(ko)
|
2007-07-25 |
2010-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
트리아진 키나제 억제제
|
CA2694953C
(en)
|
2007-07-31 |
2015-12-01 |
Androscience Corporation |
Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
|
EP2058312A1
(en)
|
2007-11-09 |
2009-05-13 |
Universita' degli Studi di Milano |
SMAC mimetic compounds as apoptosis inducers
|
US20100056524A1
(en)
|
2008-04-02 |
2010-03-04 |
Mciver Edward Giles |
Compound
|
US20120135089A1
(en)
|
2009-03-17 |
2012-05-31 |
Stockwell Brent R |
E3 ligase inhibitors
|
US8691187B2
(en)
|
2009-03-23 |
2014-04-08 |
Eli Lilly And Company |
Imaging agents for detecting neurological disorders
|
US8614201B2
(en)
|
2009-06-05 |
2013-12-24 |
Janssen Pharmaceutica Nv |
Heterocyclic amides as modulators of TRPA1
|
WO2011005510A2
(en)
|
2009-06-22 |
2011-01-13 |
Cerapedics, Inc. |
Peptide conjugates and uses thereof
|
JP2012532929A
(ja)
|
2009-07-13 |
2012-12-20 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二機能性のステープリングされたポリペプチドおよびそれらの使用
|
JP2012254939A
(ja)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
オキサゾール化合物
|
EP2784076A1
(en)
|
2009-10-28 |
2014-10-01 |
Joyant Pharmaceuticals, Inc. |
Dimeric SMAC mimetics
|
US20110164191A1
(en)
|
2010-01-04 |
2011-07-07 |
Microvision, Inc. |
Interactive Projection Method, Apparatus and System
|
US8198300B2
(en)
|
2010-04-29 |
2012-06-12 |
Universidad De Chile |
Method for preventing tau protein aggregation and treating Alzheimer's disease with a quinoline derivative compound
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
AU2011252808B2
(en)
|
2010-05-14 |
2015-05-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
|
WO2011160016A2
(en)
|
2010-06-17 |
2011-12-22 |
The Trustees Of Columbia University In The City Of New York |
E3 binding pockets and identification and use of e3 ligase inhibitors
|
EP2588129A4
(en)
|
2010-06-30 |
2014-07-09 |
Univ Brandeis |
ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
|
JP5823514B2
(ja)
|
2010-07-07 |
2015-11-25 |
アーデリクス,インコーポレーテッド |
リン酸輸送を阻害する化合物及び方法
|
JP5985473B2
(ja)
|
2010-07-13 |
2016-09-06 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
|
US9050334B2
(en)
|
2010-07-16 |
2015-06-09 |
Innov88 Llc |
MIF inhibitors and their uses
|
AU2011305315A1
(en)
|
2010-09-24 |
2013-03-28 |
The Regents Of The University Of Michigan |
Deubiquitinase inhibitors and methods for use of the same
|
US8975249B2
(en)
|
2010-11-01 |
2015-03-10 |
Celgene Avilomics Research, Inc. |
Heterocyclic compounds and uses thereof
|
CN102477033A
(zh)
*
|
2010-11-23 |
2012-05-30 |
苏州波锐生物医药科技有限公司 |
苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
WO2012078559A2
(en)
|
2010-12-07 |
2012-06-14 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
JP5923110B2
(ja)
|
2010-12-21 |
2016-05-24 |
ザ メディスンズ カンパニー (ライプチヒ) ゲーエムベーハー |
トリプシン様セリンプロテアーゼ阻害剤、その調製、ならびに凝固因子IIaおよびXaの選択的阻害剤としての使用
|
US20140243282A1
(en)
|
2010-12-31 |
2014-08-28 |
Satish Reddy Kallam |
Methods and compositions for designing novel conjugate therapeutics
|
WO2012129258A1
(en)
|
2011-03-22 |
2012-09-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
US9133164B2
(en)
|
2011-04-13 |
2015-09-15 |
Innov88 Llc |
MIF inhibitors and their uses
|
NO2694640T3
(pt)
|
2011-04-15 |
2018-03-17 |
|
|
KR20140032430A
(ko)
|
2011-05-17 |
2014-03-14 |
플렉시콘, 인코퍼레이티드 |
키나제 조절 및 그에 대한 적응증
|
US20140161720A1
(en)
|
2011-05-26 |
2014-06-12 |
The General Hospital Corporation |
Treatment of angiogenic- or vascular-associated diseases
|
US9328117B2
(en)
|
2011-06-17 |
2016-05-03 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
JP6093770B2
(ja)
|
2011-09-27 |
2017-03-08 |
アムジエン・インコーポレーテツド |
癌の治療のためのmdm2阻害剤としての複素環化合物
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
JP2015504425A
(ja)
|
2011-11-09 |
2015-02-12 |
アンサンブル・セラピューティクス |
アポトーシスのインヒビターを阻害するための大環状化合物
|
WO2013071039A1
(en)
|
2011-11-09 |
2013-05-16 |
Ensemble Therapeutics |
Macrocyclic compounds for inhibition of inhibitors of apoptosis
|
CN103172648B
(zh)
|
2011-12-20 |
2016-05-25 |
上海迪诺医药科技有限公司 |
三杂环衍生物、制备方法及应用
|
CN104582705A
(zh)
|
2012-01-10 |
2015-04-29 |
林伯士艾瑞斯公司 |
白介素-1受体相关激酶(irak)抑制剂和其用途
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
EP2802579B1
(en)
|
2012-01-13 |
2016-04-13 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
US8987311B2
(en)
|
2012-01-13 |
2015-03-24 |
Bristol-Myers Squibb Company |
Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
JP6109195B2
(ja)
|
2012-01-13 |
2017-04-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
キナーゼ阻害剤として有用な複素環置換されたピリジル化合物
|
WO2013157540A1
(ja)
|
2012-04-17 |
2013-10-24 |
富士フイルム株式会社 |
含窒素複素環化合物またはその塩
|
EP2846784A4
(en)
|
2012-05-11 |
2016-03-09 |
Univ Yale |
COMPOUNDS USEFUL FOR STIMULATING PROTEIN DEGRADATION AND METHODS USING THE SAME
|
CN104321325B
(zh)
|
2012-05-24 |
2016-11-16 |
诺华股份有限公司 |
吡咯并吡咯烷酮化合物
|
RU2014150492A
(ru)
|
2012-05-30 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Замещенные пирролидин-2-карбоксамиды
|
WO2014011712A1
(en)
|
2012-07-10 |
2014-01-16 |
Bristol-Myers Squibb Company |
Iap antagonists
|
WO2014020502A2
(en)
|
2012-07-31 |
2014-02-06 |
Novartis Ag |
Markers associated with human double minute 2 inhibitors
|
WO2014025759A1
(en)
|
2012-08-09 |
2014-02-13 |
Bristol-Myers Squibb Company |
Iap antagonists
|
TWI586668B
(zh)
|
2012-09-06 |
2017-06-11 |
第一三共股份有限公司 |
二螺吡咯啶衍生物之結晶
|
EP2897949B1
(en)
|
2012-09-18 |
2018-01-10 |
Bristol-Myers Squibb Company |
Iap antagonists
|
KR101738063B1
(ko)
|
2012-09-21 |
2017-05-19 |
아로그 파마슈티칼스, 인코퍼레이티드 |
구조적으로 활성인 인산화된 flt3 키나제의 억제 방법
|
US9603889B2
(en)
|
2012-10-02 |
2017-03-28 |
Bristol-Myers Squibb Company |
IAP antagonists
|
WO2014058691A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
EP2911669B1
(en)
|
2012-10-26 |
2024-04-10 |
The University of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
AR093404A1
(es)
|
2012-11-09 |
2015-06-03 |
Bristol Myers Squibb Co |
Compuestos macrociclicos que modulan la actividad de los inhibidores de la apoptosis
|
AU2013361694B2
(en)
|
2012-12-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
EP2934535B1
(en)
|
2012-12-20 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Substituted pyrrolopyrimidines as hdm2 inhibitors
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
NL2011274C2
(en)
|
2013-08-06 |
2015-02-09 |
Illumicare Ip B V 51 |
Groundbreaking platform technology for specific binding to necrotic cells.
|
CA2902856C
(en)
|
2013-02-28 |
2021-02-16 |
Amgen Inc. |
A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
|
CA2906538C
(en)
|
2013-03-14 |
2021-02-02 |
Ana Gonzalez Buenrostro |
Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
|
EP2970334B1
(en)
|
2013-03-15 |
2018-05-23 |
Biogen MA Inc. |
Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
|
SG11201506918WA
(en)
|
2013-03-15 |
2015-09-29 |
Bristol Myers Squibb Co |
Inhibitors of indoleamine 2,3-dioxygenase (ido)
|
JP2016528197A
(ja)
|
2013-07-01 |
2016-09-15 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Ido阻害剤
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
EP3019488B1
(en)
|
2013-07-11 |
2018-11-07 |
Bristol-Myers Squibb Company |
Ido inhibitors
|
EP3019517A1
(en)
|
2013-07-12 |
2016-05-18 |
Bristol-Myers Squibb Company |
Iap antagonists
|
CN103570726B
(zh)
|
2013-07-15 |
2016-04-06 |
上海天慈生物谷生物工程有限公司 |
N-烷基色胺酮衍生物及其制备方法和应用
|
JP2016525135A
(ja)
|
2013-07-23 |
2016-08-22 |
バイエル ファーマ アクチエンゲゼルシャフト |
BETタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド[3,4−b]ピラジノン類
|
CN105593224B
(zh)
|
2013-07-31 |
2021-05-25 |
恒元生物医药科技(苏州)有限公司 |
作为溴结构域抑制剂的新型喹唑啉酮类化合物
|
US20150051208A1
(en)
|
2013-08-14 |
2015-02-19 |
Boehringer Ingelheim International Gmbh |
Pyridinones
|
EA029981B1
(ru)
|
2013-08-27 |
2018-06-29 |
Бристол-Майерс Сквибб Компани |
Ингибиторы ido
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
US9428513B2
(en)
|
2013-11-07 |
2016-08-30 |
Boehringer Ingelheim International Gmbh |
Triazolopyrazine
|
TWI696618B
(zh)
|
2013-11-08 |
2020-06-21 |
美商英塞特控股公司 |
用於合成吲哚胺2,3-雙加氧酶抑制劑之方法
|
CN105899505B
(zh)
|
2013-11-08 |
2018-08-28 |
武田药品工业株式会社 |
用于治疗自身免疫病症的吡唑
|
CN103570727B
(zh)
|
2013-11-12 |
2015-08-19 |
复旦大学 |
一种n-苄基色胺酮衍生物及其制备方法和应用
|
PL3071203T3
(pl)
|
2013-11-18 |
2021-08-23 |
Forma Therapeutics, Inc. |
Kompozycje tetrahydrochinolinowe jako inhibitory bromodomeny bet
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
US9458156B2
(en)
|
2014-12-23 |
2016-10-04 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
AR098991A1
(es)
|
2014-01-03 |
2016-06-22 |
Bristol Myers Squibb Co |
Compuestos de nicotinamida sustituida con heteroarilo
|
SG11201605408RA
(en)
|
2014-01-10 |
2016-07-28 |
Aurigene Discovery Tech Ltd |
Indazole compounds as irak4 inhibitors
|
SI3094329T1
(sl)
|
2014-01-13 |
2019-02-28 |
Aurigene Discovery Technologies Limited |
Biciklični heterociklilni derivati kot inhibitorji IRAK4
|
JP6351306B2
(ja)
|
2014-03-06 |
2018-07-04 |
キヤノン株式会社 |
画像処理装置、画像処理装置の制御方法およびプログラム
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
EP3126330B1
(en)
|
2014-04-04 |
2019-02-27 |
Pfizer Inc |
Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
|
US20150291562A1
(en)
|
2014-04-14 |
2015-10-15 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20170166598A1
(en)
|
2014-05-13 |
2017-06-15 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
MD20160118A2
(ro)
|
2014-05-15 |
2017-04-30 |
Iteos Therapeutics |
Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
US10246456B2
(en)
|
2014-07-18 |
2019-04-02 |
Biogen Ma Inc. |
IRAK4 inhibiting agents
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
AU2015311826B2
(en)
|
2014-09-05 |
2019-05-23 |
Merck Patent Gmbh |
Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (IDO) antagonists for the treatment of cancer
|
EP3200790B1
(en)
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
US9926330B2
(en)
|
2014-09-30 |
2018-03-27 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
WO2016053771A1
(en)
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
WO2016053772A1
(en)
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
EP3247708A4
(en)
|
2015-01-20 |
2018-09-12 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the androgen receptor
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
EP3268006B1
(en)
|
2015-03-12 |
2020-01-08 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
WO2016144847A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
JP7269731B2
(ja)
|
2015-03-18 |
2023-05-09 |
アルビナス・オペレーションズ・インコーポレイテッド |
標的タンパク質の分解向上のための化合物および方法
|
NZ736709A
(en)
|
2015-05-15 |
2019-05-31 |
Gilead Sciences Inc |
Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
|
KR20180035828A
(ko)
|
2015-07-10 |
2018-04-06 |
아비나스 인코포레이티드 |
단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법
|
AU2016294450A1
(en)
|
2015-07-13 |
2017-12-07 |
Arvinas Operations, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|